Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

About this update from Tenaya Therapeutics, Inc.

[{"type":"image","alt":"Tenaya Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenaya Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QJk0bj30LJ12tZdOHYdVGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6","width":300,"height":108}},"lazy":false},{"type":"text","content":"Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy","length":190,"tagName":"p"},{"type":"text","content":"Second Late-Breaking Presentation on Sunday to Showcase Results of Cellular Reprogramming Gene Therapy Treatment in Pig Model of Ischemic Heart Failure","length":151,"tagName":"p"},{"type":"text","content":"Tenaya Management to Host Webcast Conference Call on Monday, November 10, 2025, to Review MyPEAK-1 Data","length":103,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced two late-breaking oral presentations at the American Heart Association (AHA) 2025 Scientific Sessions taking place November 7-10, 2025, in New Orleans, Louisiana.","length":448,"tagName":"p"},{"type":"text","content":"The AHA presentation of new TN-201 clinical data will include interim safety and efficacy results from dose cohorts 1 and 2 in the MyPEAK-1 Phase 1b/2a clinical trial of TN-201. TN-201 is being developed for the potential treatment of myosin-binding protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C).","length":395,"tagName":"p"},{"type":"text","content":"Details of the TN-201 clinical data presentation are as follows:","length":64,"tagName":"p"},{"type":"text","content":"Abstract Title: TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib/2a Study Evaluatin...

More updates from Tenaya Therapeutics, Inc.